This study examined whether adding levofloxacin to a standard four-drug regimen improved the 8-week culture response and compared effectiveness of 9 versus 6 months of intermittent therapy for human immunodeficiency virus -related pansusceptible pulmonary tuberculosis. Patients were randomized to receive either four or five drugs, the fifth being levofloxacin. Patients who completed induction therapy were randomized to complete 9 versus 6 months of intermittent therapy with isoniazid and rifampin. In the randomized induction phase, 97.3% of patients in the four-drug group and 95.8% in the five-drug group had sputum culture conversion at 8 weeks (P Å 1.00). In the continuation phase, one patient (2%) assigned to 9 months and two patients (3.9%) assigned to 6 months of therapy had treatment failure/relapse (P Å 1.00). In conclusion, this study showed that levofloxacin added no benefit to a highly effective, largely intermittent, four-drug induction regimen. Both 9 and 6 months of intermittent therapy were associated with low treatment failure/relapse rates.
The recent rise in the incidence of tuberculosis in the United might provide certain advantages. These include earlier discontinuation of acid-fast bacilli (AFB) isolation precautions, a de-States and the world has been attributed largely to the HIV epidemic, with the highest rates reported in geographic loca-crease in the risk of transmission, better outcomes for immunosuppressed individuals, and improved long-term outcomes [7, tions and demographic subgroups with high rates of both Mycobacterium tuberculosis and HIV infection [1] . Intermittent anti -8] . In addition, intermittent short-course regimens could facilitate treatment of patients in directly observed therapy settings tuberculous therapy has been shown to be effective and welltolerated in non-HIV-infected patients [2, 3] . However, there in a cost-effective manner. The fluoroquinolones represent the first new class of agents are few data characterizing the outcomes of intermittent-induction regimens among patients with HIV-related tuberculosis since rifampin with significant activity against M. tuberculosis [9] [10] [11] [12] . Available clinical data suggest that quinolones are valu- [4, 5] . In addition, the optimal duration of therapy for these individuals is uncertain [6] .
able in the treatment of multidrug-resistant tuberculosis (MDR-TB) [13] [14] [15] and may contribute to earlier sputum culture con-The identification of a potent induction treatment regimen that is associated with more rapid sputum culture conversion version [14] . Levofloxacin has been shown to have §2-fold greater activity against M. tuberculosis than ofloxacin in vitro, in human macrophages, and in a murine model [10, 11] . It has also been demonstrated that serum concentrations in excess of statement by the American Thoracic Society and the Centers rifampin, with no evidence of resistance to pyrazinamide; a history of receiving at least 80% of an acceptable induction for Disease Control and Prevention in 1994 supported the use of short-course (6 months) treatment for both HIV-infected regimen of treatment administered in a hospital or through a directly observed therapy program; and the ability to tolerate and uninfected persons with fully susceptible tuberculosis [6] . However, the statement indicated that in situations when the both isoniazid and rifampin. Patients were also required to be §13 years of age, have an AST level £10 times the ULN, response is judged to be delayed or suboptimal, the duration of therapy can be extended. While there are data in support of and have a total bilirubin level £2.5 times the ULN. intermittent short-course therapy for HIV-uninfected patients, few prospective comparative trials have evaluated various dura-Study Design and Treatment Regimens tions of therapy for HIV-related tuberculosis [17] . Thus, a large degree of uncertainty remains as to whether the outcome of
The study included two phases: an induction phase and a continuation phase. The induction phase was a multicenter, short-course therapy is similar to that of longer therapy.
The Terry Beirn Community Programs for Clinical Research open-label, randomized trial of 8 weeks of a 4-vs. 5-drug regimen in resistant areas and an uncontrolled trial in which on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG) initiated a study to assess two distinct questions. The the 4-drug regimen was assigned to patients in susceptible areas. The four-drug regimen consisted of isoniazid (300 mg; goal of the induction phase of the study was to characterize the response to a largely intermittent four-drug induction regi-supplied by Danbury Pharmacal, Carmel, NY) plus vitamin B 6 (50 mg; Tishcon Laboratories, Westbury, NY), rifampin men and to determine whether the addition of a fifth drug, levofloxacin, would improve the 8-week culture response for (450 mg if £50 kg or 600 mg if ú50 kg; Merrell Dow, Cincinnati), pyrazinamide (1.5 g if £50 kg or 2.0 g if ú50 kg; HIV-infected patients with active pulmonary tuberculosis who reside in geographic areas with significant rates of drug-resis-Lederle Laboratories, Wayne, NJ), and ethambutol (20 mg/kg, rounded to nearest 400 mg; Lederle), all given daily for 2 tant tuberculosis. The goal of the continuation phase of the study was to compare the treatment failure/relapse rates associ-weeks, followed by isoniazid (600 mg if £50 kg or 900 mg if ú50 kg), vitamin B 6 (50 mg), rifampin (600 mg), pyrazinam-ated with 6 vs. 9 months of intermittent therapy for those with pansusceptible pulmonary tuberculosis.
ide (2.0 g if £50 kg or 2.5 g if ú50 kg), and ethambutol (30 mg/kg, rounded to nearest 400 mg), all given thrice weekly for 6 weeks. The 5-drug regimen was identical except for the Methods addition of levofloxacin (500 mg daily for 2 weeks, followed by 750 mg thrice weekly for 6 weeks; supplied by R. W. Johnson
Study Population
Pharmaceutical Research Institute, Raritan, NJ). After 8 weeks, induction phase patients who had pansuscep-Patients were enrolled at 21 units across the United States after they signed institutional review board -approved informed tible isolates, as well as additional patients with pansusceptible baseline isolates who had completed protocol-specified accept-consent forms. Areas where §10% of patients with tuberculosis had isoniazid-resistant M. tuberculosis organisms recovered able induction regimens for HIV-related tuberculosis, were enrolled in the continuation phase of the study. The continuation (New York City area and Hawaii) are referred to herein as resistant areas; other regions, designated susceptible areas, are phase of the study was an open-label, randomized trial of 18 weeks (6 months of total therapy) or 31 weeks (9 months of those where rates of isoniazid resistance were õ10%.
Eligibility for enrollment in the induction phase of the study total therapy) of continued therapy with twice-weekly isoniazid and rifampin for patients successfully completing an 8-week included suspected diagnoses of HIV infection and pulmonary tuberculosis; an age of §18 years in resistant areas and §13 induction phase. Patients received either 600 mg (weight £50 kg) or 900 mg (weight ú50 kg) of isoniazid, 50 mg of years otherwise; a serum aspartate aminotransaminase (AST) level £10 times the upper limit of normal (ULN); a serum vitamin B 6 , and 600 mg of rifampin. The protocol strongly recommended directly observed therapy; all units had access total bilirubin level £2.5 times the ULN; and either a serum creatinine level £3 times the ULN or a creatinine clearance to such programs. rate of §50 mL/min.
Patients were ineligible for the induction phase of the study
Study Outcomes
if they had a history of MDR-TB or close contact with an MDR-TB patient, ú3 weeks of continuous antituberculous treatment The primary outcome measure for the induction phase was culture response (conversion), defined as a negative sputum immediately prior to enrollment, ú12 weeks of antituberculous therapy in the past 2 years, pregnancy, or exclusively extrapul-culture at 8 weeks after enrollment or at least two consecutive negative sputum cultures, with no subsequent positive cultures, monary tuberculosis.
The eligibility criteria for the continuation phase of the study during the 8 weeks after enrollment and a completed 8th-week visit. An unsuccessful sputum induction attempt was consid-included a confirmed diagnosis of HIV infection; a diagnosis of culture-confirmed tuberculosis susceptible to isoniazid and ered a negative sputum culture. Secondary outcome measures / 9c4c$$my09 04-17-98 15:02:26 cida UC: CID included sputum smear conversion, clinical response, survival, Growth was monitored daily in the BACTEC system, at weeks 3 and 6 on 7H11 agar plates, and at weeks 3, 6, and 8 on and adverse events.
The primary outcome measure for the continuation phase of L-J slants.
Cultures were reported as negative if growth was not de-the study was treatment failure (during therapy) or relapse (after completion of therapy). Treatment failure was defined as tected on L-J slants after 8 weeks of cultivation. For species identification, the cultures were first tested by the AccuProbe two or more positive M. tuberculosis cultures (of sputum or of specimens from another site) at least 1 month apart, with technique (Gen-Probe, San Diego). Isolates negative for the M. tuberculosis complex in the AccuProbe test were identified no intervening negative cultures, after the patient completed at least 2 months in the study and was still receiving antitubercu-with conventional biochemical tests, and those positive in the AccuProbe test were identified further as M. tuberculosis vs. lous therapy. Relapse was defined two ways: (1) a positive M. tuberculosis culture (of sputum or another specimen) after Mycobacterium bovis. Direct susceptibility testing by the proportion method was the patient's sputum culture had converted to negative and the patient had completed treatment or (2) a positive culture after used for smear-positive specimens, followed by indirect susceptibility testing, both on 7H11 agar plates. Susceptibility the patient's symptoms/signs of clinical pulmonary tuberculosis resolved and the patient completed treatment. All tuberculosis to the following drugs (concentrations, mg/mL) was tested: isoniazid (0.2 and 1), rifampin (1.0 and 5.0), and ethambutol endpoints were reviewed by an independent clinical events committee blinded to treatment group. Secondary endpoints for (7.5 and 15.0). Resistance was identified when ú1% of colonies grew in the presence of drug, compared with growth in the continuation phase of the study included adverse events, death, and new infection with an exogenous strain. a drug-free control. Susceptibilities in 7H12 broth were also determined in cases involving a positive culture of a smear-Adverse events that occurred during receipt of study medication and for 8 weeks after its discontinuation were graded on negative specimen and insufficient growth on a direct agar plate test. According to previously established standards, the a five-point scale [18] .
following critical drug concentrations (mg/mL) were incorporated in BACTEC 12B vials containing 7H12 broth: isoniazid, Evaluation and Follow-up 0.1; rifampin, 0.5; and ethambutol, 4.0. Susceptibility to pyrazinamide was tested in BACTEC 7H12 Study visits were scheduled at weeks 2, 4, 6, and 8 during the induction phase and months 1, 2, 4, 6, 8, and 10 and every broth having a pH of 6.0, with three concentrations of pyrazinamide (100 mg/mL, 300 mg/mL, and 900 mg/mL); an MIC of 4 months thereafter during the continuation phase. At baseline (enrollment), a mycobacterial blood culture and chest roentgen-£100 mg/mL was considered susceptibility, an MIC of 300 mg/mL was considered moderate susceptibility, and an MIC ography were performed, the CD4 / lymphocyte count was determined, and history of tuberculosis exposure and treatment of §900 mg/mL was considered resistance. Susceptibility to levofloxacin was tested in BACTEC 7H12 broth at a pH of and progression of HIV disease were obtained. Sputum was obtained (by induction if necessary) at enrollment and at each 6.8, with levofloxacin concentrations of 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, and 2.0 mg/mL; an MIC of £1.0 mg/mL study visit and was sent to a central mycobacteriology laboratory (National Jewish Medical and Research Center, Denver) was considered susceptibility [9] . Susceptibility testing was also performed against streptomycin, ethionamide, para-amino-for AFB smear, mycobacterial culture isolation, species identification, and drug susceptibility testing. An attempt to induce salicylic acid, capreomycin, kanamycin, amikacin, and cycloserine. sputum was made if the patient was not able to produce it independently.
Complete blood cell counts and blood chemistry values were Data Management and Analysis obtained at baseline and at weeks 4 and 8. At all study visits a clinical evaluation was conducted, including assessment of Stratified permuted block randomization was used in both phases of this study, with the research unit being the stratifica-symptoms and signs, evidence of tuberculosis and other HIVrelated complications, and antiretroviral and antiopportunistic tion factor. During the study, no investigator had access to the overall results. Toxicity and efficacy data were periodically disease medications.
reviewed by an independent data and safety monitoring board.
Several analyses of culture response in the induction phase
Bacteriologic Methods were performed. The main analysis included only those with known 8-week culture outcomes. In the second analysis, those Sputum specimens were processed with use of the NaOH-NALC digestion-decontamination method. Concentrated spu-whose data were incomplete were classified as responders (if last follow-up culture was negative) or nonresponders (if last follow-tum specimens were inoculated in BACTEC 12B vials (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD) con-up culture was positive or tuberculosis-related death occurred); those alive but for whom no follow-up culture data were available taining 7H12 broth, as well as on bi-plates containing plain and selective 7H11 agar and on Löwenstein-Jensen (L-J) slants.
were excluded. In the third analysis, only those strictly meeting / 9c4c$$my09 04-17-98 15:02:26 cida UC: CID Table 1 . Baseline characteristics of the 135 patients in the induction phase of the study who had HIVrelated tuberculosis and were randomized to receive treatment with a regimen of either four or five drugs in resistant areas or assigned to four drugs in susceptible areas.. NOTE. Susceptible areas are those where rates of resistance to isoniazid (among M. tuberculosis isolates from patients with tuberculosis) were õ10%; resistant areas are those where the rates of resistance to isoniazid were §10%. The four-drug regimen included isoniazid plus vitamin B 6 , rifampin, pyrazinamide, and ethambutol. The fivedrug regimen was identical except for the addition of levofloxacin.
* Where data were missing for some patients, the number for whom data were available is given in parentheses. Data are percentages of patients, except as otherwise noted. † For comparison of treatment groups in resistant areas.
the definition of culture response were classified as responders; In resistant areas, 87 patients were randomized to receive 4 drugs and 87 to receive 5 drugs; in susceptible areas 53 patients all others (with positive 8-week cultures or missing or incomplete were enrolled. Of the 227 patients enrolled with suspected data or who died) were classified as nonresponders. A repeatedtuberculosis and HIV infection, 135 had culture-confirmed pulmeasures analysis was used for comparisons of symptoms and monary tuberculosis (table 1) . Of these patients, 116 were HIVsmear responses over 8 weeks [19] . seropositive, 5 had had an AIDS-defining illness, and 14 were Comparisons of treatment groups were made by means of considered HIV-infected on the basis of risk behaviors (57.1% the Fisher's exact test, Student's t-test, and Wilcoxon rankwere injection drug users and 42.9% were men who had sex sum test, as appropriate. Forward stepwise proportional hazwith men), CD4 / lymphocyte counts (mean { SD, 179.9 { ards regression and logistic regression analyses were per-187.4/mm 3 ), and other factors. These 135 patients had signififormed to assess covariates related to culture response. Exact cant HIV-associated immunosuppression: 17.8% had a prior binomial 95% confidence intervals were calculated for re-AIDS diagnosis, and the overall median CD4 / lymphocyte sponse rates in the induction phase and event rates in the count was 70/mm 3 (range, 0 -805/mm 3 ). continuation phase. Time-to-event analyses were performed
With the exceptions of a prior AIDS-defining diagnosis and with use of log-rank tests and proportional hazards regresrecent household exposure to tuberculosis, baseline characterission. All P values were two-sided and unadjusted for multiple tics were similar between treatment groups in resistant areas comparisons.
( Compared with the observed response rate in the five-drug † In susceptible areas, resistance to pyrazinamide (1) or isoniazid and pyrazigroup, that in the four-drug group would have needed to be namide (1); in resistant areas (4 drugs), resistance to pyrazinamide (1), isoniazid and pyrazinamide (1), or levofloxacin (1); in resistant areas (5 drugs): resistance £81.1% to be declared significantly different with this sample to pyrazinamide (1), isoniazid and cycloserine (1), isoniazid and streptomycin size. Compared with the observed response rate in the four-drug (1) , or ethionamide and cycloserine (1) . ‡ Nonviable mixed culture of M. tuberculosis and Mycobacterium avium complex. group (97.3%), even if the five-drug group had a response rate of 100%, the difference between groups would not be statistically significant. Using the alternative analytic strategies described in Figure 1 shows the cumulative proportion of patients whose the methods section, we found no significant differences in the cultures were negative. There was no difference in the time to 8-week culture response between the regimens (table 5). The culture conversion between the regimens (P Å .70). Time to three patients with positive 8-week cultures had pansusceptible conversion was assessed by proportional hazards regression, isolates recovered both at baseline and at 8 weeks. and conversion by 2 weeks of therapy was assessed with logistic regression. Treatment group was forced into the models, and all variables in table 1 were initially included in the models, All remaining patients were alive at 8 weeks. † For comparisons of treatment groups in resistant areas over time.
In resistant areas, treatment groups did not differ with respect to sputum smear results over time (P Å .25), but at 8 weeks none of the patients assigned to 4 drugs and 6 patients (13.3%) failure during study treatment; this occurred 2 months into assigned to 5 drugs were smear-positive (P Å .03) (table 5) . treatment after the patient was assigned to the 6-month treat-Two of the smear-positive patients had positive 8th-week culment group. tures. There was no difference in symptomatic response by treatment group (table 6) . the patient assigned to 9 months of therapy who relapsed. With 100 person-years). These rates were not significantly different respect to progression of HIV disease (defined as development (P Å 1.00). There was one relapse in each of the two treatment of a new AIDS-defining clinical diagnosis or death), there were groups. Restricting the analysis to the episodes of relapse, the 30 events (39.3 per 100 person-years) in the 9-month group relative risk for 9 vs. 6 months was 1.0 (P Å 1.00). The first and 29 events (36.3 per 100 person-years) in the 6-month group relapse occurred in a patient 2 months after completion of 6 (RR, 1.1; P Å .68). A lower CD4 / lymphocyte count (dichotomonths of therapy, and the second occurred 4 months after mized at õ50/mm 3 and §50/mm 3 ) was associated with more completion of 9 months of therapy. rapid progression of HIV disease (RR, 2.2; P Å .005) and with Both of these patients had a relapse with rifampin-monoshorter survival (RR, 2.0; P Å .03), and this was independent resistant organisms, and both had advanced HIV disease (CD4 / of treatment group and history of AIDS-defining illness at study lymphocyte counts, 17/mm 3 and 26/mm 3 ); however, the first enrollment. patient had a ''relapse'' with an organism with a different molecular fingerprint by restriction fragment -length polymor-Adverse Events phism analysis of chromosomal DNA (IS6110), indicating that it was a new infection rather than a relapse. The other relapse
Secondary Outcomes for the Continuation Phase
In the induction phase of the study, there was no difference in adverse events between treatment groups (table 7) . The ma-isolate was not available for fingerprinting. There was one / 9c4c$$my09 04-17-98 15:02:26 cida UC: CID in the Denver study had cavitary pulmonary disease, compared with 10% in our study. Similarly, a study in Kenya found that those with HIV-related pulmonary tuberculosis had lower sputum bacillary counts and less-extensive pulmonary disease than HIV-uninfected patients [22] . The induction regimen may play a particularly crucial role in immunosuppressed patients, as organism load is highest in early phases of tuberculosis treatment [23] . It has been shown that inclusion of certain potent sterilizing agents in the induction phase is critical to the development of shorter-course antituberculous regimens [7, 23] . Further, Mitchison [7] and Rieder [24] separately examined data from a variety of studies in which long-term follow-up had been completed and concluded that bacteriologic response rates at 8 weeks may serve as a surrogate for the ultimate facilitate the discharge of patients from hospitals to outpatient programs of directly observed therapy.
The rise in drug-resistant tuberculosis provides a stimulus for development and evaluation of new antituberculous agents jority of adverse events were due to hepatic, hematologic, or dermatologic reactions. During the continuation phase of the and regimens. However, such evaluations are complicated by study, 8 of 50 patients (16.0%) in the 9-month group and 4 of 51 (8%) in the 6-month group experienced reportable adverse Table 7 . Percentage of patients in the induction phase of the study, events (P Å .23). In the 9-month group, six of the patients had per regimen, who developed adverse events within 8 weeks of discona grade 4 or higher adverse event, compared with two patients tinuing study induction therapy. in the 6-month group (P Å .16). The majority of the adverse events were hepatic toxicities. an intermittent induction regimen similar to the one used in * Seventy-four percent received 26 or more doses.
our study (twice weekly rather than thrice weekly and including † Seventy percent received 26 or more doses.
streptomycin rather than ethambutol) was used for HIV-unin- ‡ Seventy-six percent received 26 or more doses. § For comparisons of treatment groups in resistant areas.
fected patients in Denver [2], the 8-week culture response rate
x Adverse events were reportable if (1) they were of at least grade IV was markedly lower (75%; 95% CI, 66.5% -83.5%) than that (potentially life-threatening) on a scale of I to V and not considered to be due observed in our study. However, the populations differed in to HIV disease progression or (2) they led to the permanent discontinuation of a study drug, irrespective of severity grade.
characteristics other than HIV infection, e.g., 53% of patients / 9c4c$$my09 04-17-98 15:02:26 cida UC: CID the need for combination chemotherapy in tuberculosis treat-of patients had significantly lower median CD4 / lymphocyte counts (70/mm 3 ) than those in the Zaire study (413/mm 3 ) and ment, which confounds the ability to attribute specific outcomes to any individual agent [25] . Each of the MDR-TB cases in that the median duration of follow-up in our study was longer. Three nonrandomized prospective studies also evaluated short-the five-drug arm had a culture response, consistent with observations that the outcomes of MDR-TB are directly related to course rifampin-based therapy for HIV-infected patients [4, 29, 30] . Two studies, one conducted in Tanzania [29] and the other the number of in vitro active agents included in the regimen [15, 26 -28] .
in Ivory Coast [31], evaluated daily therapy, and a study conducted in Haiti [4] examined an intermittent supervised regimen. However, the effect of quinolones on non-MDR-TB is less well characterized. A study of a limited number of patients These studies demonstrated a relapse rate with 6 months of therapy ranging from zero to 5.4%. Thus, there appears to be a found that the early bactericidal activity of ciprofloxacin did not differ significantly from that of isoniazid, but it found growing body of evidence in support of the use of both daily and intermittent short-course therapy for patients with drug-sus-the sterilizing activity of isoniazid/rifampin/ciprofloxacin to be inferior to that of isoniazid/rifampin/pyrazinamide/ethambutol, ceptible HIV-related pulmonary tuberculosis. A wide range in relapse rates in association with 6 months of particularly among HIV-infected patients in whom the time to culture conversion was longer, and the relapse rate was higher antituberculous therapy has been noted in the studies described above, from zero to 9.9%. This range may reflect several fac-among those in the regimen including ciprofloxacin [29] . Another study of a non-HIV-infected cohort revealed no differ-tors, including characteristics of the patients (e.g., degree of immunosuppression), whether therapy was supervised (directly ences between ofloxacin and ethambutol in regimens containing isoniazid and rifampin [30] .
observed therapy), the length and completeness of follow-up, and whether recurrent episodes were confirmed or recognized In our study, no significant impact was detected with the addition of levofloxacin to the four-drug regimen in terms of on the basis of clinical diagnosis of tuberculosis. In addition, the risk for relapse may also differ on the basis of prevalence 8-week culture response, time to culture conversion, sputum smear conversion, symptom resolution, or mortality. We ob-rates of tuberculosis and the risk of new infections among exposed HIV-infected patients in communities with high rates served only a marginal relationship between the addition of levofloxacin and 2-week sputum culture conversion, consistent of tuberculosis. None of the prospective studies described above included with possibly higher early bactericidal activity, in the five-drug regimen. The study leaves unanswered the question of whether information on molecular fingerprinting, a technology that can potentially determine the true relapse rate [32] . Consistent with the addition of levofloxacin would increase the rate of culture response in a population with a higher rate of drug-resistant results of a recent report, the two relapses in our study were due to rifampin-monoresistant organisms [33] . The factors con-tuberculosis than the 18% found in our cohort. In populations similar to the one we enrolled, the addition of other drugs to tributing to this observation are currently under investigation by various groups. the four-drug regimen is unlikely to improve the 97.3% response rate observed in our study.
Tuberculosis has been associated with an increased risk of accelerated progression of HIV disease and of mortality [34] . Our study demonstrated that relapse/failure rates were low with both 6 and 9 months of therapy. Only one prior random-
The higher mortality rate has been noted in trials that compared survival of HIV-infected and HIV-uninfected patients with tu-ized study with rifampin-based regimens compared various durations of therapy for HIV-related pulmonary tuberculosis [17] .
berculosis [4, 17, 31] . Tuberculosis has also been noted to induce an increase in plasma HIV RNA and to induce HIV In that study, which was conducted in Zaire, HIV-infected patients with pulmonary tuberculosis who completed 6 months replication in an in vitro model of acute HIV infection [35] . When effective therapy is given, even in MDR-TB, the de-of therapy were randomized to 6 more months of twice-weekly isoniazid and rifampin or placebo and were compared with gree of immunosuppression has a more potent impact on survival with HIV-related tuberculosis than does the susceptibility HIV-uninfected patients who received a total of 6 months of therapy.
pattern of the involved isolate [13, 36] . In a study by Alpert et al., a CD4 / lymphocyte count of õ100 cells/mm 3 and non-In that study, the relapse rate was significantly higher among HIV-infected patients who received 6 months of therapy (9.9%) use of directly observed therapy were both significantly associated with poor survival among HIV-infected patients with tu-than among those who received 12 months of therapy (1.9%). However, the relapse rate associated with 6 months of therapy berculosis [37] . Studies have shown that early death in cases of HIV-related tuberculosis was more likely due to tuberculosis, among HIV-infected patients was not statistically different from that among HIV-uninfected patients who received treat-whereas late death was due to other HIV-related complications [38, 39] . Similar to results of other studies, the majority of ment for a similar duration. The high relapse rate in that study may reflect the fact that only half the treatment doses were deaths noted in our study were not related to tuberculosis. In studies in Kenya and Uganda, mortality rates in the first supervised or possibly the occurrence of reinfection in an area of high endemicity [17] . The lower failure/relapse rates noted 30 days of treatment were 5% and 6%, respectively [38, 40] . The early mortality observed in our study compared favorably. in our study are even more impressive given that our cohort 
